Please login to the form below

Celexa

This page shows the latest Celexa news and features for those working in and with pharma, biotech and healthcare.

protection for Abilify and former blockbuster antidepressant Lexapro/Celexa (escitalopram).

Lundbeck challenge to EC pay-for-delay ruling fails

Court upholds 94m fine for paying off firms to delay launch of Celexa generics. ... Lundbeck insists it did not go beyond the protection already offered by its patent rights on Celexa.
Lundbeck and Otsuka's Rexulti set for August launch in US

which it hopes will restore growth after the loss of patent protection on US blockbuster antidepressant Lexapro/Celexa (escitalopram).
Lundbeck CEO resigns after rule breach

Compounding this has been a legal battle with the European Commission, which ruled that Lundbeck collaborated with several other companies to delay the entry of generic competition for Celexa/ Cipramil (citalopram).
EC fines J&J and Novartis in pay-for-delay case

A case involving AstraZeneca and Nycomed was dropped last year. Earlier this year Danish pharma company Lundbeck was fined almost 94m for a pay-for-delay deal involving its antidepressant
Lundbeck presses on with cost-saving programme

its big-selling antidepressant Celexa/ Cipramil (citalopram).

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....